Loading...

Lawrence Fong, MD

Title(s)Professor, Medicine
SchoolSchool of Medicine
Address513 Parnassus Ave, HSE
San Francisco CA 94143
Phone415-514-3160
EmailLawrence.Fong@ucsf.edu
ORCID ORCID Icon0000-0002-6428-428X Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Columbia, New YorkBA05/1988
    Stanford, StanfordMD05/1992
    Collapse Awards and Honors
    1990Stanford Alumni Medical Scholar
    1993Alpha Omega Alpha
    1997American Society of Clinical Oncology Young Investigator Award
    1997American Cancer Society Post-Doctoral Fellowship
    2002American Association for Cancer Research Scholar-in-Training Award
    2003V Foundation Scholar
    2014Earle Chiles Visiting Professorship
    2015American Society for Clinical Investigation

    Collapse Overview 
    Collapse Overview
    Lawrence Fong, M.D. is the Efim Guzik Distinguished Professor in Cancer Biology and leads the Cancer Immunotherapy Program at the UCSF. He also co-directs the Parker Institute of Cancer Immunotherapy at UCSF and co-leads the Cancer Immunity Program in the Helen Diller Family Comprehensive Cancer Center. He is a physician-scientist in the Department of Medicine, Division of Hematology/Oncology directing both a translational research program and a research lab. He has focused on cancer immunotherapy for over 20 years and has been involved in both pre-clinical and clinical studies of FDA-approved immunotherapies including sipuleucel-T and immune checkpoint inhibitors. Dr. Fong’s research focuses on understanding the mechanisms that underlie clinical response and resistance to immunotherapies.

    Collapse Research 
    Collapse Research Activities and Funding
    Mechanisms of Exosome Driven Immunoregulation of Cancer Progression
    NIH/NCI U01CA244452Sep 23, 2019 - Aug 31, 2024
    Role: Co-Principal Investigator
    Molecular and immune drivers of immunotherapy responsiveness in prostate cancer
    NIH/NCI U01CA233100Sep 19, 2018 - Aug 31, 2023
    Role: Co-Principal Investigator
    Determinants of prostate cancer sensitivity to PD-1 blockade
    NIH/NCI R01CA223484Jan 16, 2018 - Dec 31, 2022
    Role: Principal Investigator
    Immunotherapy of human bladder cancer
    NIH/NCI R01CA194511Jul 2, 2015 - Jun 30, 2020
    Role: Principal Investigator
    Prostatitis and Prostate Cancer Development
    NIH/NCI R01CA163012Sep 1, 2012 - Jun 30, 2017
    Role: Principal Investigator
    Prostate Cancer Immunotherapy
    NIH/NCI R01CA136753Mar 1, 2009 - Feb 28, 2014
    Role: Principal Investigator
    Dendritics Cell Immunotherapy for Colorectal Cancer
    NIH/NCI R01CA102303Apr 1, 2004 - Mar 31, 2009
    Role: Principal Investigator
    DENDRITIC CELL IMMUNOTHERAPY FOR LUNG AND COLON CANCER
    NIH/NCI K23CA082584Jul 6, 1999 - Jun 30, 2004
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites
    Collapse In The News
    Collapse Featured Videos

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. An Analysis of Isoclonal Antibody Formats Suggests a Role for Measuring PD-L1 with Low Molecular Weight PET Radiotracers. Mol Imaging Biol. 2020 Aug 19. Wei J, Wang YH, Lee CY, Truillet C, Oh DY, Xu Y, Ruggero D, Flavell RR, VanBrocklin HF, Seo Y, Craik CS, Fong L, Wang CI, Evans MJ. PMID: 32813112.
      View in: PubMed   Mentions:    Fields:    
    2. Phase II Study of Ipilimumab in Men With Metastatic Prostate Cancer With an Incomplete Response to Androgen Deprivation Therapy. Front Oncol. 2020; 10:1381. Graff JN, Stein MN, Surana R, Al Rabadi L, Liu E, Fong L, Bailey S, Latour E, Newby TA, Moran AE, Beer TM. PMID: 32850444.
      View in: PubMed   Mentions:
    3. Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer. Mol Ther. 2020 Jul 21. Ko AH, Jordan AC, Tooker E, Lacey SF, Chang RB, Li Y, Venook AP, Tempero M, Damon L, Fong L, O'Hara MH, Levine BL, Melenhorst JJ, Plesa G, June CH, Beatty GL. PMID: 32730744.
      View in: PubMed   Mentions:    Fields:    
    4. The DNA methylation landscape of advanced prostate cancer. Nat Genet. 2020 Jul 13. Zhao SG, Chen WS, Li H, Foye A, Zhang M, Sjöström M, Aggarwal R, Playdle D, Liao A, Alumkal JJ, Das R, Chou J, Hua JT, Barnard TJ, Bailey AM, Chow ED, Perry MD, Dang HX, Yang R, Moussavi-Baygi R, Zhang L, Alshalalfa M, Laura Chang S, Houlahan KE, Shiah YJ, Beer TM, Thomas G, Chi KN, Gleave M, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Yvonne Kim M, Fong L, Spratt DE, Morgan TM, Bose R, Huang FW, Li H, Chesner L, Shenoy T, Goodarzi H, Asangani IA, Sandhu S, Lang JM, Mahajan NP, Lara PN, Evans CP, Febbo P, Batzoglou S, Knudsen KE, He HH, Huang J, Zwart W, Costello JF, Luo J, Tomlins SA, Wyatt AW, Dehm SM, Ashworth A, Gilbert LA, Boutros PC, Farh K, Chinnaiyan AM, Maher CA, Small EJ, Quigley DA, Feng FY. PMID: 32661416.
      View in: PubMed   Mentions:    Fields:    
    5. Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer. Cell. 2020 Jun 25; 181(7):1612-1625.e13. Oh DY, Kwek SS, Raju SS, Li T, McCarthy E, Chow E, Aran D, Ilano A, Pai CS, Rancan C, Allaire K, Burra A, Sun Y, Spitzer MH, Mangul S, Porten S, Meng MV, Friedlander TW, Ye CJ, Fong L. PMID: 32497499.
      View in: PubMed   Mentions:    Fields:    
    6. Cancer Moonshot Immuno-Oncology Translational Network (IOTN): accelerating the clinical translation of basic discoveries for improving immunotherapy and immunoprevention of cancer. J Immunother Cancer. 2020 06; 8(1). Annapragada A, Sikora A, Bollard C, Conejo-Garcia J, Cruz CR, Demehri S, Demetriou M, Demirdjian L, Fong L, Horowitz M, Hutson A, Kadash-Edmondson K, Kufe D, Lipkin S, Liu S, McCarthy C, Morgan M, Morris Z, Pan Y, Pasquini M, Schoenberger S, Van Allen E, Vilar E, Xing Y, Zha W, Odunsi A. PMID: 32554617.
      View in: PubMed   Mentions:    Fields:    
    7. Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T. J Natl Cancer Inst. 2020 Jun 01; 112(6):562-573. Madan RA, Antonarakis ES, Drake CG, Fong L, Yu EY, McNeel DG, Lin DW, Chang NN, Sheikh NA, Gulley JL. PMID: 32145020.
      View in: PubMed   Mentions:    Fields:    
    8. Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma. Clin Cancer Res. 2020 Jun 15; 26(12):2827-2837. Algazi AP, Twitty CG, Tsai KK, Le M, Pierce R, Browning E, Hermiz R, Canton DA, Bannavong D, Oglesby A, Francisco M, Fong L, Pittet MJ, Arlauckas SP, Garris C, Levine LP, Bifulco C, Ballesteros-Merino C, Bhatia S, Gargosky S, Andtbacka RHI, Fox BA, Rosenblum MD, Daud AI. PMID: 32376655.
      View in: PubMed   Mentions:    Fields:    
    9. Combination immunotherapy induces distinct T-cell repertoire responses when administered to patients with different malignancies. J Immunother Cancer. 2020 May; 8(1). Cham J, Zhang L, Kwek S, Paciorek A, He T, Fong G, Oh DY, Fong L. PMID: 32376721.
      View in: PubMed   Mentions:    Fields:    
    10. Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma. BJU Int. 2020 Jul; 126(1):73-82. Pal SK, McDermott DF, Atkins MB, Escudier B, Rini BI, Motzer RJ, Fong L, Joseph RW, Oudard S, Ravaud A, Bracarda S, Suárez C, Lam ET, Choueiri TK, Ding B, Quach C, Hashimoto K, Schiff C, Piault-Louis E, Powles T. PMID: 32233107.
      View in: PubMed   Mentions: 1     Fields:    
    11. Immune Checkpoint Blockade for Prostate Cancer: Niche Role or Next Breakthrough? Am Soc Clin Oncol Educ Book. 2020 Mar; 40:1-18. de Almeida DVP, Fong L, Rettig MB, Autio KA. PMID: 32343604.
      View in: PubMed   Mentions:    Fields:    
    12. Tissue Determinants of Human NK Cell Development, Function, and Residence. Cell. 2020 02 20; 180(4):749-763.e13. Dogra P, Rancan C, Ma W, Toth M, Senda T, Carpenter DJ, Kubota M, Matsumoto R, Thapa P, Szabo PA, Li Poon MM, Li J, Arakawa-Hoyt J, Shen Y, Fong L, Lanier LL, Farber DL. PMID: 32059780.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    13. Immune Checkpoint Inhibition in Prostate Cancer. Trends Cancer. 2020 Mar; 6(3):174-177. Nicholson LT, Fong L. PMID: 32101720.
      View in: PubMed   Mentions:    Fields:    
    14. Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients. Ann Oncol. 2020 04; 31(4):532-540. Algazi A, Bhatia S, Agarwala S, Molina M, Lewis K, Faries M, Fong L, Levine LP, Franco M, Oglesby A, Ballesteros-Merino C, Bifulco CB, Fox BA, Bannavong D, Talia R, Browning E, Le MH, Pierce RH, Gargosky S, Tsai KK, Twitty C, Daud AI. PMID: 32147213.
      View in: PubMed   Mentions:    Fields:    
    15. TCR Convergence in Individuals Treated With Immune Checkpoint Inhibition for Cancer. Front Immunol. 2019; 10:2985. Looney TJ, Topacio-Hall D, Lowman G, Conroy J, Morrison C, Oh D, Fong L, Zhang L. PMID: 31993050.
      View in: PubMed   Mentions: 1     Fields:    
    16. Intratumoral Plasmid IL12 Electroporation Therapy in Patients with Advanced Melanoma Induces Systemic and Intratumoral T-cell Responses. Cancer Immunol Res. 2020 02; 8(2):246-254. Greaney SK, Algazi AP, Tsai KK, Takamura KT, Chen L, Twitty CG, Zhang L, Paciorek A, Pierce RH, Le MH, Daud AI, Fong L. PMID: 31852717.
      View in: PubMed   Mentions:    Fields:    
    17. Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer. Cancer Discov. 2020 01; 10(1):40-53. Fong L, Hotson A, Powderly JD, Sznol M, Heist RS, Choueiri TK, George S, Hughes BGM, Hellmann MD, Shepard DR, Rini BI, Kummar S, Weise AM, Riese MJ, Markman B, Emens LA, Mahadevan D, Luke JJ, Laport G, Brody JD, Hernandez-Aya L, Bonomi P, Goldman JW, Berim L, Renouf DJ, Goodwin RA, Munneke B, Ho PY, Hsieh J, McCaffery I, Kwei L, Willingham SB, Miller RA. PMID: 31732494.
      View in: PubMed   Mentions: 3     Fields:    
    18. Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP [MVI-816]) in Patients With Progressive, Nonmetastatic, Castration-Sensitive Prostate Cancer. J Clin Oncol. 2019 12 20; 37(36):3507-3517. McNeel DG, Eickhoff JC, Johnson LE, Roth AR, Perk TG, Fong L, Antonarakis ES, Wargowski E, Jeraj R, Liu G. PMID: 31644357.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    19. Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response. J Immunother Cancer. 2019 10 18; 7(1):267. Keenan BP, Fong L, Kelley RK. PMID: 31627733.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimals
    20. Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer-A Phase 1 Study. JAMA Oncol. 2019 Jun 02. Uldrick TS, Gonçalves PH, Abdul-Hay M, Claeys AJ, Emu B, Ernstoff MS, Fling SP, Fong L, Kaiser JC, Lacroix AM, Lee SY, Lundgren LM, Lurain K, Parsons CH, Peeramsetti S, Ramaswami R, Sharon E, Sznol M, Wang CJ, Yarchoan R, Cheever MA. PMID: 31154457.
      View in: PubMed   Mentions: 11     Fields:    
    21. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Ann Oncol. 2019 06 01; 30(6):970-976. Fradet Y, Bellmunt J, Vaughn DJ, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Nam K, Frenkl TL, Perini RF, de Wit R, Bajorin DF. PMID: 31050707.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    22. Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory. Cell. 2019 04 04; 177(2):414-427.e13. Poggio M, Hu T, Pai CC, Chu B, Belair CD, Chang A, Montabana E, Lang UE, Fu Q, Fong L, Blelloch R. PMID: 30951669.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansAnimalsCells
    23. The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target. J Natl Cancer Inst. 2019 03 01; 111(3):301-310. Zhao SG, Lehrer J, Chang SL, Das R, Erho N, Liu Y, Sjöström M, Den RB, Freedland SJ, Klein EA, Karnes RJ, Schaeffer EM, Xu M, Speers C, Nguyen PL, Ross AE, Chan JM, Cooperberg MR, Carroll PR, Davicioni E, Fong L, Spratt DE, Feng FY. PMID: 30321406.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    24. Clonal Deletion of Tumor-Specific T Cells by Interferon-? Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade. Immunity. 2019 02 19; 50(2):477-492.e8. Pai CS, Huang JT, Lu X, Simons DM, Park C, Chang A, Tamaki W, Liu E, Roybal KT, Seagal J, Chen M, Hagihara K, Wei XX, DuPage M, Kwek SS, Oh DY, Daud A, Tsai KK, Wu C, Zhang L, Fasso M, Sachidanandam R, Jayaprakash A, Lin I, Casbon AJ, Kinsbury GA, Fong L. PMID: 30737146.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    25. Immunity in the Time of Metastases. Immunity. 2018 12 18; 49(6):1002-1003. Oh DY, Fong L. PMID: 30566878.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    26. Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity. J Clin Invest. 2019 01 02; 129(1):349-363. Pai CS, Simons DM, Lu X, Evans M, Wei J, Wang YH, Chen M, Huang J, Park C, Chang A, Wang J, Westmoreland S, Beam C, Banach D, Bowley D, Dong F, Seagal J, Ritacco W, Richardson PL, Mitra S, Lynch G, Bousquet P, Mankovich J, Kingsbury G, Fong L. PMID: 30530991.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    27. Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med. 2018 Dec; 24(12):1941. McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, Sznol M, Hainsworth J, Rathmell WK, Stadler WM, Hutson T, Gore ME, Ravaud A, Bracarda S, Suárez C, Danielli R, Gruenwald V, Choueiri TK, Nickles D, Jhunjhunwala S, Piault-Louis E, Thobhani A, Qiu J, Chen DS, Hegde PS, Schiff C, Fine GD, Powles T. PMID: 30291359.
      View in: PubMed   Mentions: 2     Fields:    
    28. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell. 2018 10 18; 175(3):889. Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY. PMID: 30340047.
      View in: PubMed   Mentions: 6     Fields:    
    29. Neoadjuvant sipuleucel-T induces both Th1 activation and immune regulation in localized prostate cancer. Oncoimmunology. 2019; 8(1):e1486953. Hagihara K, Chan S, Zhang L, Oh DY, Wei XX, Simko J, Fong L. PMID: 30546940.
      View in: PubMed   Mentions:
    30. Itraconazole as a Noncastrating Treatment for Biochemically Recurrent Prostate Cancer: A Phase 2 Study. Clin Genitourin Cancer. 2019 Feb; 17(1):e92-e96. Lee M, Hong H, Kim W, Zhang L, Friedlander TW, Fong L, Lin AM, Small EJ, Wei XX, Rodvelt TJ, Miralda B, Stocksdale B, Ryan CJ, Aggarwal R. PMID: 30327180.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    31. A Preclinical Assessment of 89Zr-atezolizumab Identifies a Requirement for Carrier Added Formulations Not Observed with 89Zr-C4. Bioconjug Chem. 2018 10 17; 29(10):3476-3482. Moroz A, Lee CY, Wang YH, Hsiao JC, Sevillano N, Truillet C, Craik CS, Fong L, Wang CI, Evans MJ. PMID: 30227708.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    32. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell. 2018 07 26; 174(3):758-769.e9. Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY. PMID: 30033370.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCells
    33. Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer Immunity. Cell Rep. 2018 06 12; 23(11):3262-3274. Wang D, Quiros J, Mahuron K, Pai CC, Ranzani V, Young A, Silveria S, Harwin T, Abnousian A, Pagani M, Rosenblum MD, Van Gool F, Fong L, Bluestone JA, DuPage M. PMID: 29898397.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCells
    34. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med. 2018 06; 24(6):749-757. McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, Sznol M, Hainsworth J, Rathmell WK, Stadler WM, Hutson T, Gore ME, Ravaud A, Bracarda S, Suárez C, Danielli R, Gruenwald V, Choueiri TK, Nickles D, Jhunjhunwala S, Piault-Louis E, Thobhani A, Qiu J, Chen DS, Hegde PS, Schiff C, Fine GD, Powles T. PMID: 29867230.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansCTClinical Trials
    35. Immunotherapy for Prostate Cancer: Where Do We Go From Here?-PART 2: Checkpoint Inhibitors, Immunotherapy Combinations, Tumor Microenvironment Modulation, and Cellular Therapies. Oncology (Williston Park). 2018 06; 32(6):e65-e73. Patel A, Fong L. PMID: 29940064.
      View in: PubMed   Mentions: 1     Fields:    
    36. Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer. J Clin Oncol. 2018 06 01; 36(16):1579-1587. Vaughn DJ, Bellmunt J, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Li H, Perini RF, Bajorin DF, de Wit R. PMID: 29590008.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    37. Immunotherapy for Prostate Cancer: Where Do We Go From Here?-PART 1: Prostate Cancer Vaccines. Oncology (Williston Park). 2018 03 15; 32(3):112-20. Patel A, Fong L. PMID: 29548065.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    38. Shuffling the deck with CTLA-4 therapy: Deep sequencing of rearranged TCRB genes demonstrates T cell repertoire remodeling in cancer patients. Oncoimmunology. 2018; 7(4):e956016. Cha E, Fong L. PMID: 29632706.
      View in: PubMed   Mentions:
    39. A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone- and/or Enzalutamide-Refractory Metastatic Castration-Resistant Prostate Cancer. Oncologist. 2018 06; 23(6):656-e64. Wei XX, Siegel AP, Aggarwal R, Lin AM, Friedlander TW, Fong L, Kim W, Louttit M, Chang E, Zhang L, Ryan CJ. PMID: 29487219.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    40. TGFß attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018 02 22; 554(7693):544-548. Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Kadel EE, Koeppen H, Astarita JL, Cubas R, Jhunjhunwala S, Banchereau R, Yang Y, Guan Y, Chalouni C, Ziai J, Senbabaoglu Y, Santoro S, Sheinson D, Hung J, Giltnane JM, Pierce AA, Mesh K, Lianoglou S, Riegler J, Carano RAD, Eriksson P, Höglund M, Somarriba L, Halligan DL, van der Heijden MS, Loriot Y, Rosenberg JE, Fong L, Mellman I, Chen DS, Green M, Derleth C, Fine GD, Hegde PS, Bourgon R, Powles T. PMID: 29443960.
      View in: PubMed   Mentions: 227     Fields:    Translation:HumansAnimalsCells
    41. Single-cell RNA sequencing reveals gene expression signatures of breast cancer-associated endothelial cells. Oncotarget. 2018 Feb 16; 9(13):10945-10961. Sun Z, Wang CY, Lawson DA, Kwek S, Velozo HG, Owyong M, Lai MD, Fong L, Wilson M, Su H, Werb Z, Cooke DL. PMID: 29541388.
      View in: PubMed   Mentions: 1     Fields:    
    42. Clinical Variables Associated With Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Sipuleucel-T Immunotherapy. Clin Genitourin Cancer. 2018 06; 16(3):184-190.e2. Wei XX, Perry J, Chang E, Zhang L, Hiatt RA, Ryan CJ, Small EJ, Fong L. PMID: 29352713.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    43. Imaging PD-L1 Expression with ImmunoPET. Bioconjug Chem. 2018 01 17; 29(1):96-103. Truillet C, Oh HLJ, Yeo SP, Lee CY, Huynh LT, Wei J, Parker MFL, Blakely C, Sevillano N, Wang YH, Shen YS, Olivas V, Jami KM, Moroz A, Jego B, Jaumain E, Fong L, Craik CS, Chang AJ, Bivona TG, Wang CI, Evans MJ. PMID: 29125731.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCells
    44. Combination central tolerance and peripheral checkpoint blockade unleashes antimelanoma immunity. JCI Insight. 2017 09 21; 2(18). Bakhru P, Zhu ML, Wang HH, Hong LK, Khan I, Mouchess M, Gulati AS, Starmer J, Hou Y, Sailer D, Lee S, Zhao F, Kirkwood JM, Moschos S, Fong L, Anderson MS, Su MA. PMID: 28931755.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCells
    45. Early Probiotic Supplementation for Eczema and Asthma Prevention: A Randomized Controlled Trial. Pediatrics. 2017 Sep; 140(3). Cabana MD, McKean M, Caughey AB, Fong L, Lynch S, Wong A, Leong R, Boushey HA, Hilton JF. PMID: 28784701.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    46. High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer. Clin Genitourin Cancer. 2017 12; 15(6):733-741.e1. Friedlander TW, Graff JN, Zejnullahu K, Anantharaman A, Zhang L, Paz R, Premasekharan G, Russell C, Huang Y, Kim W, Aggarwal RR, Lin AM, Fong L, Alumkal JJ, Beer TM, Sharifi N, Alyamani M, Dittamore R, Small EJ, Paris PL, Ryan CJ. PMID: 28655452.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    47. 3D: diversity, dynamics, differential testing - a proposed pipeline for analysis of next-generation sequencing T cell repertoire data. BMC Bioinformatics. 2017 Feb 27; 18(1):129. Zhang L, Cham J, Paciorek A, Trager J, Sheikh N, Fong L. PMID: 28241742.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    48. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med. 2017 03 16; 376(11):1015-1026. Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Poehlein CH, Perini RF, Bajorin DF. PMID: 28212060.
      View in: PubMed   Mentions: 277     Fields:    Translation:HumansCTClinical Trials
    49. Systemic Immunity Is Required for Effective Cancer Immunotherapy. Cell. 2017 01 26; 168(3):487-502.e15. Spitzer MH, Carmi Y, Reticker-Flynn NE, Kwek SS, Madhireddy D, Martins MM, Gherardini PF, Prestwood TR, Chabon J, Bendall SC, Fong L, Nolan GP, Engleman EG. PMID: 28111070.
      View in: PubMed   Mentions: 114     Fields:    Translation:HumansAnimalsCells
    50. Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire. Cancer Res. 2017 03 15; 77(6):1322-1330. Oh DY, Cham J, Zhang L, Fong G, Kwek SS, Klinger M, Faham M, Fong L. PMID: 28031229.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    51. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma. J Immunother Cancer. 2016; 4:92. McNeel DG, Bander NH, Beer TM, Drake CG, Fong L, Harrelson S, Kantoff PW, Madan RA, Oh WK, Peace DJ, Petrylak DP, Porterfield H, Sartor O, Shore ND, Slovin SF, Stein MN, Vieweg J, Gulley JL. PMID: 28031820.
      View in: PubMed   Mentions: 8     Fields:    
    52. Television During Meals in the First 4 Years of Life. Clin Pediatr (Phila). 2017 Jun; 56(7):659-666. Thimmig LM, Cabana MD, Bentz MG, Potocka K, Beck A, Fong L, Chao C, Caughey AB, Wong A, McKean M. PMID: 28503997.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    53. Can Prostate Cancer Really Respond to Immunotherapy? J Clin Oncol. 2017 01; 35(1):4-5. Kim W, Fong L. PMID: 28034060.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    54. Immunotherapy in genitourinary malignancies. Curr Opin Urol. 2016 11; 26(6):501-7. Wattenberg MM, Fong L, Madan RA, Gulley JL. PMID: 27471994.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    55. Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer. Cancer Immunol Res. 2016 11; 4(11):948-958. Wei XX, Chan S, Kwek S, Lewis J, Dao V, Zhang L, Cooperberg MR, Ryan CJ, Lin AM, Friedlander TW, Rini B, Kane C, Simko JP, Carroll PR, Small EJ, Fong L. PMID: 27688020.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    56. Clonotypic Diversification of Intratumoral T Cells Following Sipuleucel-T Treatment in Prostate Cancer Subjects. Cancer Res. 2016 07 01; 76(13):3711-8. Sheikh N, Cham J, Zhang L, DeVries T, Letarte S, Pufnock J, Hamm D, Trager J, Fong L. PMID: 27216195.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCellsCTClinical Trials
    57. Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2016 Nov 15; 22(22):5461-5471. Choueiri TK, Fishman MN, Escudier B, McDermott DF, Drake CG, Kluger H, Stadler WM, Perez-Gracia JL, McNeel DG, Curti B, Harrison MR, Plimack ER, Appleman L, Fong L, Albiges L, Cohen L, Young TC, Chasalow SD, Ross-Macdonald P, Srivastava S, Jure-Kunkel M, Kurland JF, Simon JS, Sznol M. PMID: 27169994.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCellsCTClinical Trials
    58. Prospects for the use of ipilimumab in treating advanced prostate cancer. Expert Opin Biol Ther. 2016; 16(3):421-32. Wei XX, Fong L, Small EJ. PMID: 26698365.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    59. GM-CSF and ipilimumab therapy in metastatic melanoma: Clinical outcomes and immunologic responses. Oncoimmunology. 2016 Apr; 5(4):e1101204. Kwek SS, Kahn J, Greaney SK, Lewis J, Cha E, Zhang L, Weber RW, Leonard L, Markovic SN, Fong L, Spitler LE. PMID: 27141383.
      View in: PubMed   Mentions:
    60. Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions. Expert Rev Vaccines. 2015; 14(12):1529-41. Wei XX, Fong L, Small EJ. PMID: 26488270.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    61. On the Verge: Immunotherapy for Colorectal Carcinoma. J Natl Compr Canc Netw. 2015 Aug; 13(8):970-8. Oh DY, Venook AP, Fong L. PMID: 26285242.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimals
    62. Transglutaminase 4 as a prostate autoantigen in male subfertility. Sci Transl Med. 2015 Jun 17; 7(292):292ra101. Landegren N, Sharon D, Shum AK, Khan IS, Fasano KJ, Hallgren Å, Kampf C, Freyhult E, Ardesjö-Lundgren B, Alimohammadi M, Rathsman S, Ludvigsson JF, Lundh D, Motrich R, Rivero V, Fong L, Giwercman A, Gustafsson J, Perheentupa J, Husebye ES, Anderson MS, Snyder M, Kämpe O. PMID: 26084804.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCells
    63. Preexisting Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with Ipilimumab. Cancer Immunol Res. 2015 Sep; 3(9):1008-16. Kwek SS, Lewis J, Zhang L, Weinberg V, Greaney SK, Harzstark AL, Lin AM, Ryan CJ, Small EJ, Fong L. PMID: 25968455.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCellsCTClinical Trials
    64. A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2015 Sep 01; 21(17):3862-9. Small EJ, Lance RS, Gardner TA, Karsh LI, Fong L, McCoy C, DeVries T, Sheikh NA, GuhaThakurta D, Chang N, Redfern CH, Shore ND. PMID: 25925891.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCellsCTClinical Trials
    65. Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens. Clin Cancer Res. 2014 Dec 15; 20(24):6269-76. Kim W, Zhang L, Wilton JH, Fetterly G, Mohler JL, Weinberg V, Morse A, Szmulewitz RZ, Friedlander TW, Fong L, Lin AM, Harzstark AL, Molina A, Small EJ, Ryan CJ. PMID: 25336698.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    66. Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer. J Natl Cancer Inst. 2014 Nov; 106(11). Fong L, Carroll P, Weinberg V, Chan S, Lewis J, Corman J, Amling CL, Stephenson RA, Simko J, Sheikh NA, Sims RB, Frohlich MW, Small EJ. PMID: 25255802.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCellsCTClinical Trials
    67. Immune evasion mediated by tumor-derived lactate dehydrogenase induction of NKG2D ligands on myeloid cells in glioblastoma patients. Proc Natl Acad Sci U S A. 2014 Sep 02; 111(35):12823-8. Crane CA, Austgen K, Haberthur K, Hofmann C, Moyes KW, Avanesyan L, Fong L, Campbell MJ, Cooper S, Oakes SA, Parsa AT, Lanier LL. PMID: 25136121.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCells
    68. Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients. Sci Transl Med. 2014 May 28; 6(238):238ra70. Cha E, Klinger M, Hou Y, Cummings C, Ribas A, Faham M, Fong L. PMID: 24871131.
      View in: PubMed   Mentions: 115     Fields:    Translation:Humans
    69. Enhancement of an anti-tumor immune response by transient blockade of central T cell tolerance. J Exp Med. 2014 May 05; 211(5):761-8. Khan IS, Mouchess ML, Zhu ML, Conley B, Fasano KJ, Hou Y, Fong L, Su MA, Anderson MS. PMID: 24752296.
      View in: PubMed   Mentions: 33     Fields:    Translation:AnimalsCells
    70. The end of the beginning: circulating tumor cells as a biomarker in castration-resistant prostate cancer. J Clin Oncol. 2014 Apr 10; 32(11):1104-6. Friedlander TW, Fong L. PMID: 24616311.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    71. Beyond sipuleucel-T: immune approaches to treating prostate cancer. Curr Treat Options Oncol. 2014 Mar; 15(1):115-26. Cheng ML, Fong L. PMID: 24402184.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    72. Neoadjuvant therapy for localized prostate cancer: Examining mechanism of action and efficacy within the tumor. Urol Oncol. 2016 Apr; 34(4):182-92. Lou DY, Fong L. PMID: 24495446.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    73. Effects of RANKL-Targeted Therapy in Immunity and Cancer. Front Oncol. 2014 Jan 07; 3:329. Cheng ML, Fong L. PMID: 24432249.
      View in: PubMed   Mentions:
    74. Diversity of antigen-specific responses induced in vivo with CTLA-4 blockade in prostate cancer patients. J Immunol. 2012 Oct 01; 189(7):3759-66. Kwek SS, Dao V, Roy R, Hou Y, Alajajian D, Simko JP, Small EJ, Fong L. PMID: 22956585.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    75. Unmasking the immune recognition of prostate cancer with CTLA4 blockade. Nat Rev Cancer. 2012 03 01; 12(4):289-97. Kwek SS, Cha E, Fong L. PMID: 22378189.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimals
    76. A phase II study of insulin-like growth factor receptor inhibition with nordihydroguaiaretic acid in men with non-metastatic hormone-sensitive prostate cancer. Oncol Rep. 2012 Jan; 27(1):3-9. Friedlander TW, Weinberg VK, Huang Y, Mi JT, Formaker CG, Small EJ, Harzstark AL, Lin AM, Fong L, Ryan CJ. PMID: 21971890.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    77. Immunotherapy for prostate cancer: biology and therapeutic approaches. J Clin Oncol. 2011 Sep 20; 29(27):3677-85. Cha E, Fong L. PMID: 21825260.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    78. Interplay between CD8a+ dendritic cells and monocytes in response to Listeria monocytogenes infection attenuates T cell responses. PLoS One. 2011 Apr 29; 6(4):e19376. Kapadia D, Sadikovic A, Vanloubbeeck Y, Brockstedt D, Fong L. PMID: 21559416.
      View in: PubMed   Mentions: 10     Fields:    Translation:AnimalsCells
    79. A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma. Cancer. 2011 Sep 15; 117(18):4194-200. Harzstark AL, Small EJ, Weinberg VK, Sun J, Ryan CJ, Lin AM, Fong L, Brocks DR, Rosenberg JE. PMID: 21387258.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    80. Islet transplantation in type 1 diabetic patients using calcineurin inhibitor-free immunosuppressive protocols based on T-cell adhesion or costimulation blockade. Transplantation. 2010 Dec 27; 90(12):1595-601. Posselt AM, Szot GL, Frassetto LA, Masharani U, Tavakol M, Amin R, McElroy J, Ramos MD, Kerlan RK, Fong L, Vincenti F, Bluestone JA, Stock PG. PMID: 20978464.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    81. Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. Cancer Res. 2011 Jan 15; 71(2):550-60. Moltzahn F, Olshen AB, Baehner L, Peek A, Fong L, Stöppler H, Simko J, Hilton JF, Carroll P, Blelloch R. PMID: 21098088.
      View in: PubMed   Mentions: 100     Fields:    Translation:Humans
    82. Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II study. Urol Oncol. 2012 Jul-Aug; 30(4):408-14. Friedlander TW, Weinberg VK, Small EJ, Sharib J, Harzstark AL, Lin AM, Fong L, Ryan CJ. PMID: 20884247.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    83. Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. J Clin Oncol. 2010 Jul 20; 28(21):3485-90. Chung KY, Gore I, Fong L, Venook A, Beck SB, Dorazio P, Criscitiello PJ, Healey DI, Huang B, Gomez-Navarro J, Saltz LB. PMID: 20498386.
      View in: PubMed   Mentions: 68     Fields:    Translation:HumansCTClinical Trials
    84. An autoimmune response to odorant binding protein 1a is associated with dry eye in the Aire-deficient mouse. J Immunol. 2010 Apr 15; 184(8):4236-46. DeVoss JJ, LeClair NP, Hou Y, Grewal NK, Johannes KP, Lu W, Yang T, Meagher C, Fong L, Strauss EC, Anderson MS. PMID: 20237294.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimals
    85. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol. 2010 Mar 20; 28(9):1481-8. Ryan CJ, Smith MR, Fong L, Rosenberg JE, Kantoff P, Raynaud F, Martins V, Lee G, Kheoh T, Kim J, Molina A, Small EJ. PMID: 20159824.
      View in: PubMed   Mentions: 123     Fields:    Translation:HumansCTClinical Trials
    86. HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase. Cancer Immunol Immunother. 2010 Jun; 59(6):943-53. Olson BM, Frye TP, Johnson LE, Fong L, Knutson KL, Disis ML, McNeel DG. PMID: 20140431.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    87. Therapeutic vaccines for prostate cancer. Curr Opin Mol Ther. 2010 Feb; 12(1):77-85. Cha E, Fong L. PMID: 20140819.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    88. Developing immunotherapy as legitimate therapy for patients with prostate cancer. J Clin Oncol. 2010 Mar 01; 28(7):1085-7. Small EJ, Fong L. PMID: 20100956.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    89. Identification of an autoantigen demonstrates a link between interstitial lung disease and a defect in central tolerance. Sci Transl Med. 2009 Dec 02; 1(9):9ra20. Shum AK, DeVoss J, Tan CL, Hou Y, Johannes K, O'Gorman CS, Jones KD, Sochett EB, Fong L, Anderson MS. PMID: 20368189.
      View in: PubMed   Mentions: 26     Fields:    Translation:Animals
    90. A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies. Clin Cancer Res. 2009 Sep 01; 15(17):5569-75. Chien AJ, Illi JA, Ko AH, Korn WM, Fong L, Chen LM, Kashani-Sabet M, Ryan CJ, Rosenberg JE, Dubey S, Small EJ, Jahan TM, Hylton NM, Yeh BM, Huang Y, Koch KM, Moasser MM. PMID: 19706807.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    91. An aberrant prostate antigen-specific immune response causes prostatitis in mice and is associated with chronic prostatitis in humans. J Clin Invest. 2009 Jul; 119(7):2031-41. Hou Y, DeVoss J, Dao V, Kwek S, Simko JP, McNeel DG, Anderson MS, Fong L. PMID: 19603556.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    92. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res. 2009 Jan 15; 69(2):609-15. Fong L, Kwek SS, O'Brien S, Kavanagh B, McNeel DG, Weinberg V, Lin AM, Rosenberg J, Ryan CJ, Rini BI, Small EJ. PMID: 19147575.
      View in: PubMed   Mentions: 104     Fields:    Translation:HumansCellsCTClinical Trials
    93. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol. 2008 Nov 10; 26(32):5275-83. Fong L, Small EJ. PMID: 18838703.
      View in: PubMed   Mentions: 90     Fields:    Translation:HumansAnimals
    94. CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. Blood. 2008 Aug 15; 112(4):1175-83. Kavanagh B, O'Brien S, Lee D, Hou Y, Weinberg V, Rini B, Allison JP, Small EJ, Fong L. PMID: 18523152.
      View in: PubMed   Mentions: 80     Fields:    Translation:HumansCellsCTClinical Trials
    95. SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade. Proc Natl Acad Sci U S A. 2008 Mar 04; 105(9):3509-14. Fassò M, Waitz R, Hou Y, Rim T, Greenberg NM, Shastri N, Fong L, Allison JP. PMID: 18303116.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansAnimalsCells
    96. Distinct CD8+ T cell repertoires primed with agonist and native peptides derived from a tumor-associated antigen. J Immunol. 2008 Feb 01; 180(3):1526-34. Hou Y, Kavanagh B, Fong L. PMID: 18209048.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    97. Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome. J Urol. 2007 Dec; 178(6):2372-6; discussion 2377. Ryan CJ, Weinberg V, Rosenberg J, Fong L, Lin A, Kim J, Small EJ. PMID: 17936834.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    98. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides. J Immunother. 2007 Oct; 30(7):762-72. Kavanagh B, Ko A, Venook A, Margolin K, Zeh H, Lotze M, Schillinger B, Liu W, Lu Y, Mitsky P, Schilling M, Bercovici N, Loudovaris M, Guillermo R, Lee SM, Bender J, Mills B, Fong L. PMID: 17893568.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCellsCTClinical Trials
    99. Immunotherapy for prostate cancer. Curr Oncol Rep. 2007 May; 9(3):226-33. Fong L, Small EJ. PMID: 17430695.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    100. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res. 2007 Mar 15; 13(6):1810-5. Small EJ, Tchekmedyian NS, Rini BI, Fong L, Lowy I, Allison JP. PMID: 17363537.
      View in: PubMed   Mentions: 122     Fields:    Translation:HumansCTClinical Trials
    101. Spontaneous autoimmunity prevented by thymic expression of a single self-antigen. J Exp Med. 2006 Nov 27; 203(12):2727-35. DeVoss J, Hou Y, Johannes K, Lu W, Liou GI, Rinn J, Chang H, Caspi RR, Caspi R, Fong L, Anderson MS. PMID: 17116738.
      View in: PubMed   Mentions: 121     Fields:    Translation:Animals
    102. A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy. BJU Int. 2006 Oct; 98(4):763-9. Lin AM, Rini BI, Weinberg V, Fong K, Ryan CJ, Rosenberg JE, Fong L, Small EJ. PMID: 16796694.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    103. Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Cancer. 2006 Jul 01; 107(1):67-74. Rini BI, Weinberg V, Fong L, Conry S, Hershberg RM, Small EJ. PMID: 16736512.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCellsCTClinical Trials
    104. Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factor. J Urol. 2006 Jun; 175(6):2087-91. Rini BI, Fong L, Weinberg V, Kavanaugh B, Small EJ. PMID: 16697809.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    105. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther. 2006 Jul; 14(1):107-17. Small EJ, Carducci MA, Burke JM, Rodriguez R, Fong L, van Ummersen L, Yu DC, Aimi J, Ando D, Working P, Kirn D, Wilding G. PMID: 16690359.
      View in: PubMed   Mentions: 73     Fields:    Translation:HumansCellsCTClinical Trials
    106. Immunotherapy for prostate cancer. Curr Urol Rep. 2006 May; 7(3):239-46. Fong L, Small EJ. PMID: 16630528.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    107. CTLA-4 blockade: autoimmunity as treatment. J Clin Oncol. 2005 Dec 10; 23(35):8926-8. Kapadia D, Fong L. PMID: 16204008.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCells
    108. Immunotherapy for prostate cancer. Semin Oncol. 2003 Oct; 30(5):649-58. Fong L, Small EJ. PMID: 14571412.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    109. Induction of immunity to tumor-associated antigens following dendritic cell vaccination of cancer patients. Clin Immunol. 2003 Jan; 106(1):10-5. Engleman EG, Fong L. PMID: 12584045.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    110. Productive infection of plasmacytoid dendritic cells with human immunodeficiency virus type 1 is triggered by CD40 ligation. J Virol. 2002 Nov; 76(21):11033-41. Fong L, Mengozzi M, Abbey NW, Herndier BG, Engleman EG. PMID: 12368346.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansCells
    111. In vivo manipulation of dendritic cells to induce therapeutic immunity. Blood. 2002 Mar 01; 99(5):1676-82. Merad M, Sugie T, Engleman EG, Fong L. PMID: 11861283.
      View in: PubMed   Mentions: 20     Fields:    Translation:AnimalsCells
    112. Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J Immunol. 2001 Dec 15; 167(12):7150-6. Fong L, Brockstedt D, Benike C, Breen JK, Strang G, Ruegg CL, Engleman EG. PMID: 11739538.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    113. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci U S A. 2001 Jul 17; 98(15):8809-14. Fong L, Hou Y, Rivas A, Benike C, Yuen A, Fisher GA, Davis MM, Engleman EG. PMID: 11427731.
      View in: PubMed   Mentions: 84     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    114. Dendritic cells injected via different routes induce immunity in cancer patients. J Immunol. 2001 Mar 15; 166(6):4254-9. Fong L, Brockstedt D, Benike C, Wu L, Engleman EG. PMID: 11238679.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansCellsCTClinical Trials
    115. Differentiation of myeloid dendritic cells into CD8alpha-positive dendritic cells in vivo. Blood. 2000 Sep 01; 96(5):1865-72. Merad M, Fong L, Bogenberger J, Engleman EG. PMID: 10961888.
      View in: PubMed   Mentions: 13     Fields:    Translation:AnimalsCells
    116. Dendritic cells in cancer immunotherapy. Annu Rev Immunol. 2000; 18:245-73. Fong L, Engleman EG. PMID: 10837059.
      View in: PubMed   Mentions: 93     Fields:    Translation:HumansAnimalsCells
    117. Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration. Clin Immunol. 1999 Jul; 92(1):67-75. Brockstedt DG, Podsakoff GM, Fong L, Kurtzman G, Mueller-Ruchholtz W, Engleman EG. PMID: 10413654.
      View in: PubMed   Mentions: 43     Fields:    Translation:AnimalsCells
    118. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med. 1999 Jun; 5(6):677-85. Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS, Johnson D, Swetter S, Thompson J, Greenberg PD, Roederer M, Davis MM. PMID: 10371507.
      View in: PubMed   Mentions: 249     Fields:    Translation:HumansCells
    119. Donor blood monocytes but not T or B cells facilitate long-term allograft survival after total lymphoid irradiation. Transplantation. 1998 Sep 15; 66(5):585-93. Hayamizu K, Zeng D, Huie P, Garcia-Ojeda ME, Bloch DA, Fong L, Engleman EG, Sibley RK, Strober S. PMID: 9753336.
      View in: PubMed   Mentions:    Fields:    Translation:AnimalsCells
    120. Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer. J Immunol. 1997 Oct 01; 159(7):3113-7. Fong L, Ruegg CL, Brockstedt D, Engleman EG, Laus R. PMID: 9317107.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansAnimalsCells
    121. Introduction of soluble proteins into the MHC class I pathway by conjugation to an HIV tat peptide. J Immunol. 1997 Aug 15; 159(4):1666-8. Kim DT, Mitchell DJ, Brockstedt DG, Fong L, Nolan GP, Fathman CG, Engleman EG, Rothbard JB. PMID: 9257826.
      View in: PubMed   Mentions: 24     Fields:    Translation:AnimalsCells
    Lawrence's Networks
    Concepts (452)
    Derived automatically from this person's publications.
    _
    Co-Authors (99)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _